Glycomic Biomarkers of Ageing

The glycome is the complete set of glycans in a cell, tissue, or biological sample. Glycans are branched carbohydrate structures attached to many proteins and lipids, and glycomics studies their composition and distribution at scale. In ageing research, blood-based work has focused particularly on glycans attached to IgG and to the wider set of plasma or serum proteins. [1] [2]

Who This Is Useful For

This page is useful for readers comparing glycan-based age estimates with epigenetic, proteomic, or metabolomic biomarkers. It explains what a glycomic profile measures, which age-related patterns have been reproduced, and why an estimated “glycan age” should be interpreted as a model-dependent research result rather than a clinical diagnosis. [1] [3]

What Glycomic Biomarkers Measure

Unlike DNA sequence, glycan structures are not copied from a single template. Their production depends on enzymes, substrate availability, cellular state, and the protein to which they are attached. This makes the glycome responsive to both inherited biology and changing physiological conditions, but it also makes glycomic signals difficult to attribute to ageing alone. [1] [7]

IgG is studied frequently because it is abundant in blood and carries a conserved N-glycosylation site in its Fc region. Variation in galactose, sialic acid, fucose, and bisecting N-acetylglucosamine at this site can alter how IgG interacts with immune receptors and complement. [3] [6]

Common Glycomic Measures at a Glance

These categories overlap but are not interchangeable: an IgG-specific profile, a total plasma profile, and a site-specific glycopeptide panel sample different biological mixtures. [1] [2] [5]

Recurring Age-Associated Patterns

Early serum studies found that under-galactosylated N-glycans increased after approximately midlife, while a core-fucosylated, bi-galactosylated structure decreased. Studies focused on IgG similarly found more agalactosylated and bisected structures with increasing age. [2] [4]

In a study of 5,117 people from four European populations, three IgG glycan features together explained up to 58% of chronological-age variance. That is evidence for a strong population-level age signal, but it also leaves substantial unexplained variation and does not establish that the glycans measure every ageing process. [3]

Broader plasma glycoproteomics also detects age-associated signals outside isolated IgG. A site-specific study of 97 healthy volunteers identified 41 age-associated glycopeptides and built a five-feature age model, illustrating both the information available in the plasma glycome and the relatively small scale of some discovery cohorts. [5]

Relationship to Immune Function

Glycosylation is not only a passive label on IgG. Fc glycans influence antibody interactions with Fc receptors and complement, so age-linked changes may accompany changes in inflammatory signalling. However, a glycan associated with both age and inflammation cannot by itself show whether ageing caused the change, inflammation caused it, or both reflect a shared process. [3] [6]

Why Sex and Hormonal Context Matter

Age trajectories are not identical across sexes. Observational and experimental evidence indicates that menopause is associated with increased agalactosylated IgG, while manipulation of oestrogen signalling changes IgG galactosylation. A glycan-age model that ignores sex and menopausal context may therefore combine endocrine transition with other components of ageing. [6]

Measurement and Interpretation Limits

Glycomic results depend on what is measured and how it is measured. Released-glycan chromatography, capillary electrophoresis, and mass-spectrometry-based glycopeptide methods differ in structural detail, protein specificity, and coverage. O-linked glycans have generally been less extensively characterized than N-linked glycans because their analytical workflows are more difficult to standardize. [1]

Specificity is another limitation. Age-related diseases, inflammatory activity, medication, body composition, smoking, alcohol exposure, and hormonal state can influence the circulating glycome. These influences may be biologically meaningful, but they prevent a glycan profile from serving as a pure readout of intrinsic ageing. [1] [6] [7]

Population transfer also requires care. Much of the foundational IgG-clock evidence came from European cohorts, and glycan distributions can vary with ancestry, environment, age range, and cohort selection. Models therefore require external validation and calibration before comparisons across populations or laboratories are treated as equivalent. [3] [5]

Evidence Quality and Interpretation

Confidence is strong that circulating N-glycan profiles change with chronological age and that reduced IgG galactosylation is among the most repeatedly observed patterns. This conclusion is supported by multiple cohorts and by studies using both IgG-specific and broader serum measurements. [2] [3] [4]

Confidence is moderate that composite glycan models capture physiologically relevant variation beyond chronological age. Associations with immune function and health-related traits make this plausible, but the residual from an age-prediction model has no single agreed biological meaning. [3] [7]

Confidence is weaker for using one glycan-age result as a standalone clinical assessment. There is no universal assay, reference population, or accepted threshold that converts an individual score into a diagnosis of accelerated ageing. [1] [5]

What This Does Not Mean

• It does not mean lower galactosylation is specific to ageing rather than inflammation, disease, or hormonal context. [1] [6]
• It does not mean a glycan clock measures the age of every organ or biological system. [3] [5]
• It does not mean two assays labelled “glycan age” necessarily measure the same glycan structures or use the same model. [1]
• It does not mean an association between a glycan and age establishes that the glycan causes ageing. [2] [3]

Practical Interpretation Examples

• If a glycan model estimates an older age than chronological age: the difference is a statistical residual shaped by the model, reference cohort, and current physiological context, not a literal count of years lost. [3] [7]
• If agalactosylated IgG is higher: the result is consistent with a pattern seen in older and more inflammatory states, but is not specific enough to identify its cause by itself. [1] [4]
• If plasma and IgG glycomic estimates disagree: they may be reflecting different protein mixtures and biological processes rather than a measurement error. [1] [5]

Related Reading

• Categories of Ageing Biomarkers
• Proteomic Clocks and Biological Age
• Metabolomic Biomarkers of Ageing
• Limitations of Ageing Biomarkers

Summary

Glycomic biomarkers capture age-associated changes in the carbohydrate structures attached to circulating proteins, with IgG N-glycosylation providing the best-developed example. The repeated shift toward lower galactosylation and sialylation makes the glycome informative for population research, and composite models can estimate part of chronological-age variation. Their interpretation remains conditional on immune state, hormones, disease, population, and assay design, so glycan age is best viewed as one biological domain rather than a definitive measure of whole-body ageing. [1] [3] [6]

References

1. Paton, B., Suarez, M., Herrero, P., & Canela, N. (2021). Glycosylation biomarkers associated with age-related diseases and current methods for glycan analysis. International Journal of Molecular Sciences. https://pmc.ncbi.nlm.nih.gov/articles/PMC8198018/
2. Vanhooren, V., et al. (2007). N-glycomic changes in serum proteins during human aging. Rejuvenation Research. https://pubmed.ncbi.nlm.nih.gov/18047421/
3. Krištić, J., et al. (2014). Glycans are a novel biomarker of chronological and biological ages. The Journals of Gerontology: Series A. https://pubmed.ncbi.nlm.nih.gov/24325898/
4. Parekh, R., Roitt, I., Isenberg, D., Dwek, R., & Rademacher, T. (1988). Age-related galactosylation of the N-linked oligosaccharides of human serum IgG. Journal of Experimental Medicine. https://pubmed.ncbi.nlm.nih.gov/3133487/
5. Merleev, A. A., et al. (2020). A site-specific map of the human plasma glycome and its age and gender-associated alterations. Scientific Reports. https://www.nature.com/articles/s41598-020-73588-x
6. Ercan, A., et al. (2017). Estrogens regulate glycosylation of IgG in women and men. JCI Insight. https://pubmed.ncbi.nlm.nih.gov/28239652/
7. Mijakovac, A., et al. (2022). Heritability of the glycan clock of biological age. Frontiers in Cell and Developmental Biology. https://pubmed.ncbi.nlm.nih.gov/36619858/